Ozekibart

Ozekibart (0.00001-100 nmol/L; 1 hour at 4°C) binds specifically to DR5 expressed on DR5-transfected ExpiCHO-S cells with an apparent K_d of 0.107 nmol/L^[1].
Ozekibart (0.00001-100 nmol/L, with 3.5 nmol/L TRAIL; 1 hour at 4°C) competes with TRAIL for DR5 binding on DR5-transfected ExpiCHO-S cells with an IC₅₀ of 0.17 nmol/L^[1].
Ozekibart (0.00001-100 nmol/L, with 50 μmol/L Z-VAD-FMK; 5.5 hours at 37°C) does not mediate ADCC activity against DR5-transfected ExpiCHO-S cells in a Jurkat CD16a^V158 ADCC reporter assay^[1].
Ozekibart (10 μg/mL; overnight at 4°C for immobilization, 1 hour at room temperature for complement serum incubation) does not bind complement component C1q, confirming lack of CDC activity^[1].
Ozekibart (titrated concentrations; 1 hour at room temperature) binds specifically to human DR5, with no cross-reactivity to DR4, Decoy R1, or Decoy R2 in an ELISA binding assay^[1].
Ozekibart (0.0001-100 nmol/L; 16 hours) induces caspase-dependent cytotoxicity in H-EMC-SS chondrosarcoma cells with an EC₅₀ of 3.3 pmol/L^[1].
Ozekibart (0.0001-100 nmol/L; 16 hours, imaged every 30 minutes) induces rapid, caspase-dependent activation of caspase-3/7 in H-EMC-SS chondrosarcoma cells^[1].
Ozekibart (tested concentrations; 20 minutes at 37°C, 5% CO₂ followed by 42 hours incubation with media or 10 mg/mL IVIG) does not induce significant hepatotoxicity in HepaRG hepatic progenitor cells, even in the presence of IVIG as a source of preexisting antidrug antibodies^[1].
Ozekibart (0.000001-10 nmol/L; 7 days) does not induce cytotoxicity in 3D human liver microtissues at concentrations up to 10 nmol/L after 7 days of treatment^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.